Rhythm Pharmaceuticals, Inc. (RYTM)
94.78
+2.60
(+2.82%)
USD |
NASDAQ |
Oct 28, 16:00
92.96
-1.82
(-1.92%)
After-Hours: 20:00
Rhythm Pharmaceuticals Enterprise Value : 6.237B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 6.237B |
| October 26, 2026 | 6.050B |
| October 23, 2026 | 6.036B |
| October 22, 2026 | 6.149B |
| October 21, 2026 | 5.992B |
| October 20, 2026 | 6.100B |
| October 19, 2026 | 5.965B |
| October 16, 2026 | 5.823B |
| October 15, 2026 | 5.947B |
| October 14, 2026 | 5.860B |
| October 13, 2026 | 5.853B |
| October 12, 2026 | 6.074B |
| October 09, 2026 | 6.140B |
| October 08, 2026 | 6.062B |
| October 07, 2026 | 5.980B |
| October 06, 2026 | 6.140B |
| October 05, 2026 | 6.255B |
| October 02, 2026 | 6.281B |
| October 01, 2026 | 6.321B |
| September 30, 2026 | 6.446B |
| September 29, 2026 | 6.480B |
| September 28, 2026 | 6.676B |
| September 25, 2026 | 6.683B |
| September 24, 2026 | 6.659B |
| September 23, 2026 | 6.654B |
| Date | Value |
|---|---|
| September 22, 2026 | 6.725B |
| September 21, 2026 | 6.694B |
| September 18, 2026 | 6.617B |
| September 17, 2026 | 6.707B |
| September 16, 2026 | 6.638B |
| September 15, 2026 | 6.553B |
| September 14, 2026 | 6.943B |
| September 11, 2026 | 7.099B |
| September 10, 2026 | 6.926B |
| September 09, 2026 | 6.848B |
| September 08, 2026 | 6.899B |
| September 04, 2026 | 6.963B |
| September 03, 2026 | 7.111B |
| September 02, 2026 | 7.148B |
| September 01, 2026 | 7.101B |
| August 31, 2026 | 7.197B |
| August 28, 2026 | 7.268B |
| August 27, 2026 | 7.637B |
| August 26, 2026 | 7.592B |
| August 25, 2026 | 7.694B |
| August 24, 2026 | 7.562B |
| August 21, 2026 | 7.463B |
| August 20, 2026 | 7.389B |
| August 19, 2026 | 7.857B |
| August 18, 2026 | 7.824B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 30.01B |
| BioMarin Pharmaceutical, Inc. | 14.06B |
| Cytokinetics, Inc. | 8.638B |
| Exelixis, Inc. | 15.59B |
| Ionis Pharmaceuticals, Inc. | 7.416B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.30M |
| Revenue (Quarterly) | 71.26M |
| Total Expenses (Quarterly) | 120.55M |
| EPS Diluted (Quarterly) | -0.7342 |
| Gross Profit Margin (Quarterly) | 87.39% |
| Profit Margin (Quarterly) | -69.19% |
| Earnings Yield | -3.29% |
| Normalized Earnings Yield | -3.279 |